Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

Completed · Phase 1

Conditions studied: Metastatic Prostate Cancer, Cancer of the Prostate, Prostate Cancer

In brief

This clinical trial will examine a novel combination of anti-OX40 to induce proliferation of memory and effector T cells in conjunction with cyclophosphamide (CTX) and radiation to induce tumor antigen release with the overall goal of promoting an immune response against prostate cancer.

Key facts

Study ID

NCT01303705

Run by

Providence Health & Services

People needed

13

Starts

2010-10-14

Expected to finish

2016-07-05

Last updated by the study team

2018-08-29

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patients with measurable or evaluable metastatic adenocarcinoma of the prostate. Either histologic or cytologic diagnosis is acceptable
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 (Appendix A.)
• Age 18 years old or above
• Laboratory values (performed within 28 days prior to enrollment) as follows:
• WBC ≥ 2000/microlitre
• Serum creatinine < 1.5 X upper limit of laboratory normal
• Hgb > 8g/dl (patients may be transfused to reach this level)
• Platelets > 100,000 cells/mm3
• Total bilirubin < 1.5 X upper limit of laboratory normal, unless due to Gilbert's disease
• AST (SGOT) and ALT (SGPT) < 2.5 X upper limit of laboratory normal
• Alkaline phosphatase < 2.5 X upper limit of laboratory normal (If alkaline phosphatase > 2.5 X upper limit of laboratory normal due to bone metastases, then patient is eligible.)
• HIV 1 and 2 antibody Negative
• Hepatitis B surface antigen Negative
• Hepatitis C antibody Negative
• PSA > 2 ng/ml
• Testosterone < 50 ng/ml
• Confirmed radiographic and/or PSA progression (using PCWG2 definitions) after at least one androgen ablation regimen and docetaxel.Patients who refuse docetaxel chemotherapy or who are not candidates for docetaxel are eligible to enroll.
• At least one bone metastatic lesion amenable to radiation
• Ability to give informed consent and comply with the protocol. Patients with a history of psychiatric illness must be judged able to understand the investigational nature of the study and the risks associated with the therapy
• No active bleeding
• No clinical coagulopathy (INR < 1.5, PT < 16 seconds, PTT < 38 seconds)
• Anticipated lifespan greater than 12 weeks
• Patients on LHRH agonists or bisphosphonates prior to study enrollment should continue these medications without change

You may not qualify if…

• Active infection.
• Active autoimmune disease.
• Previous treatment with mouse monoclonal antibodies
• Need for chronic maintenance oral steroids.
• Active brain metastatic disease. Patients with treated brain metastases with surgery, gamma-knife radiosurgery or radiation and stable for at least 4 weeks and off steroids are eligible.
• Any medical or psychiatric condition that in the opinion of the PI would preclude compliance with study procedures.

Where it is running

• Providence Portland Medical Center — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.